Edgestream Partners L.P. acquired a new position in shares of Medtronic PLC (NYSE:MDT – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 98,938 shares of the medical technology company’s stock, valued at approximately $8,537,000.
A number of other hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its stake in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after purchasing an additional 838,220 shares during the last quarter. State Street Corp lifted its holdings in Medtronic by 2.7% in the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Bank of America Corp DE lifted its holdings in Medtronic by 5.4% in the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after purchasing an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares during the last quarter. Finally, Amundi boosted its stake in Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after purchasing an additional 1,616,739 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.
Key Headlines Impacting Medtronic
These are some of the MDT headlines that stood out recently:
- Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery in the U.S. The expanded authorization opens access to an estimated 3.5 million annual U.S. cases and procedures that represent more than half of U.S. soft-tissue surgeries, increasing Hugo’s commercial opportunity. Article: Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
- Positive Sentiment: Medtronic plans to acquire Contego Medical for $380 million, adding carotid and peripheral vascular technologies to its portfolio. The deal builds on an existing U.S. distribution relationship and could strengthen its vascular-intervention business. Article: Medtronic to buy Contego Medical for $380M
- Neutral Sentiment: A preview of Medtronic’s Q2 results points to Cardiovascular momentum, particularly cardiac ablation, with Neuroscience and Diabetes also expected to contribute growth. These are expectations ahead of the earnings report, not reported results. Article: MDT Q2 Earnings Preview
Insider Activity
In other news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares of the company’s stock, valued at $10,167,936. This represents a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by insiders.
Medtronic Stock Performance
Shares of Medtronic stock opened at $102.24 on Wednesday. The business’s 50 day moving average price is $94.09 and its 200 day moving average price is $88.49. The company has a market cap of $130.78 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.41 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts predict that Medtronic PLC will post 5.98 EPS for the current year.
Medtronic Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s payout ratio is currently 70.94%.
Analysts Set New Price Targets
A number of research firms have recently issued reports on MDT. Mizuho set a $115.00 target price on shares of Medtronic in a report on Wednesday, September 2nd. Stifel Nicolaus increased their target price on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research report on Wednesday, September 2nd. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Monday. Bank of America upped their price objective on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Nineteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.28.
Check Out Our Latest Stock Report on Medtronic
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Articles
- Five stocks we like better than Medtronic
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
